Morgan Stanley
CYCN

Morgan Stanley’s Cyclerion Therapeutics CYCN Stock Holding History

Morgan Stanley’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1
Closed -$2 – 8457
2026
Q1 		$2 Hold
1
– – ﹤0.01% 8256
2025
Q4 		$2 Sell
1
-648
-100% -$1.16K ﹤0.01% 8173
2025
Q3 		$1.49K Hold
649
– – ﹤0.01% 7352
2025
Q2 		$1.89K Hold
649
– – ﹤0.01% 7237
2025
Q1 		$1.62K Hold
649
– – ﹤0.01% 7214
2024
Q4 		$2.09K Hold
649
– – ﹤0.01% 7190
2024
Q3 		$1.68K Hold
649
– – ﹤0.01% 7163
2024
Q2 		$1.49K Hold
649
– – ﹤0.01% 7104
2024
Q1 		$2.08K Sell
649
-49
-7% -$157 ﹤0.01% 7060
2023
Q4 		$2.34K Sell
698
-125
-15% -$361 ﹤0.01% 7016
2023
Q3 		$2.82K Hold
823
– – ﹤0.01% 7051
2023
Q2 		$3.39K Buy
823
+221
+37% +$1.15K ﹤0.01% 7072
2023
Q1 		$5.22K Buy
602
+438
+267% +$5.53K ﹤0.01% 7038
2022
Q4 		$2.16K Sell
164
-6
-4% -$71 ﹤0.01% 7353
2022
Q3 		$3K Sell
170
-93
-35% -$1.6K ﹤0.01% 7374
2022
Q2 		$3K Sell
263
-1,696
-87% -$24.3K ﹤0.01% 7503
2022
Q1 		$43K Sell
1,959
-1,684
-46% -$40.6K ﹤0.01% 6779
2021
Q4 		$125K Sell
3,643
-82
-2% -$3.87K ﹤0.01% 6306
2021
Q3 		$229K Buy
3,725
+217
+6% +$14.2K ﹤0.01% 5926
2021
Q2 		$274K Buy
3,508
+1,619
+86% +$101K ﹤0.01% 5855
2021
Q1 		$105K Sell
1,889
-18,769
-91% -$1.41M ﹤0.01% 5977
2020
Q4 		$1.26M Buy
20,658
+17,540
+563% +$1.2M ﹤0.01% 4516
2020
Q3 		$379K Buy
3,118
+2,714
+672% +$310K ﹤0.01% 4777
2020
Q2 		$48K Buy
404
+265
+191% +$22.2K ﹤0.01% 5683
2020
Q1 		$7K Sell
139
-1,520
-92% -$108K ﹤0.01% 6102
2019
Q4 		$89K Buy
1,659
+1,160
+232% +$108K ﹤0.01% 5692
2019
Q3 		$121K Buy
499
+385
+338% +$83.2K ﹤0.01% 5368
2019
Q2 		$25K Buy
+114
New +$32.3K ﹤0.01% 5857

Other funds holding CYCN

KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RC
Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Morgan Stanley's CYCN Position: Q2 2026 in Review

Morgan Stanley sold out of Cyclerion Therapeutics (CYCN) in Q2 2026, closing a stake of 1 share — an estimated $2 sold.

Morgan Stanley first reported a position in CYCN in Q2 2019 and held it in 28 quarters. The position peaked at $1.26M in Q4 2020. 21 funds tracked by Wall St. Rank hold CYCN as of Q2 2026.

  • Morgan Stanley reported no remaining Cyclerion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Morgan Stanley sold 1 Cyclerion Therapeutics share in Q2 2026, an estimated $2.
  • Morgan Stanley first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 28 quarters.
  • Morgan Stanley's Cyclerion Therapeutics position peaked at $1.26M in Q4 2020.
  • 21 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.